JP Morgan Maintains Overweight on Nurix Therapeutics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Nurix Therapeutics (NASDAQ:NRIX) and raises the price target from $31 to $34.
July 15, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Eric Joseph maintains an Overweight rating on Nurix Therapeutics and raises the price target from $31 to $34.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence in Nurix Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100